Fig. 5From: Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectivesa HDAC inhibitors have been linked to a variety of severe and/or significant side responses; b Distribution of grade 3/4 toxicities in clinical trials (Table 2) of histone deacetylase inhibitors. Figure created with BioRender.comBack to article page